Safety and Efficacy Evaluation of High Intensity Focused Ultrasound Device in Eyebrow Lifting

Last updated: May 12, 2026
Sponsor: CLASSYS Inc.
Overall Status: Completed

Phase

N/A

Condition

Skin Aging

Treatment

HIFU treatment with ULTRAFOMER MPT

Clinical Study ID

NCT06724510
CLSGQDWJJCHS
  • Ages 20-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to assess the safety and efficacy of the high-intensity focused ultrasound (HIFU) device, ULTRAFORMER MPT (UF4-M400), developed by CLASSYS Inc., for eyebrow lifting. This study is a prospective, multicenter, evaluator-blinded, randomized, non-treatment-controlled, superiority clinical trial.

The main questions the study seeks to answer are:

Does the ULTRAFORMER MPT device effectively lift eyebrows? Is the safety profile of the ULTRAFORMER MPT device acceptable? Researchers will compare the investigational device to a non-treatment control group to determine whether the HIFU device demonstrates superiority in eyebrow lifting outcomes.

Participant Details:

Participants will receive a single treatment session using the investigational device or be assigned to the non-treatment control group.

Follow-up will occur over 3 months to evaluate the effectiveness and safety of the treatment.

Outcomes:

Primary Outcome: Eyebrow lifting improvement, assessed through standardized photographic evaluation and other aesthetic measurement tools.

Secondary Outcomes: Participant satisfaction using the Global Aesthetic Improvement Scale (GAIS) and pain assessment using a Visual Analog Scale (VAS).

Safety Measures: Monitoring for adverse events (AEs) and serious adverse events (SAEs) throughout the study period.

This trial aims to provide robust evidence supporting the use of the ULTRAFORMER MPT for non-invasive eyebrow lifting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age: 20 to 65 years old at the time of consent.

  2. Condition: Forehead skin laxity with Forehead Lines Grading Scale score of 1-3.

  3. Consent: Ability to understand trial details, voluntarily participate, and complywith treatment and follow-up.

Exclusion

Exclusion Criteria:

  1. Skin Conditions: Hyperpigmentation, tattoos, scars, active skin diseases, or otherconditions (e.g., eczema, psoriasis, vitiligo) in the treatment area that may affectefficacy or increase risk.

  2. Medical Devices or Implants: Presence of metal implants or embedded electronicdevices in the treatment area.

  3. Health Conditions: Severe dysfunction of vital organs (e.g., heart, liver, kidneys),autoimmune diseases, or uncontrolled diabetes.

  4. Medications: Recent use of anti-thrombotic agents, NSAIDs, or other drugs affectingcoagulation within one week before screening.

  5. Prior Treatments: Use of fillers (e.g., hyaluronic acid, collagen) or cosmeticprocedures (e.g., laser therapy, botulinum toxin) in the treatment area within thespecified timeframes.

  6. Pregnancy: Women who are pregnant, nursing, or not using birth control during thetrial.

Study Design

Total Participants: 180
Treatment Group(s): 1
Primary Treatment: HIFU treatment with ULTRAFOMER MPT
Phase:
Study Start date:
November 18, 2024
Estimated Completion Date:
December 18, 2025

Connect with a study center

  • Beijing Anzhen Hospital of Capital Medical University

    Beijing,
    China

    Site Not Available

  • Emergency General Hospital

    Beijing,
    China

    Site Not Available

  • TheThird Hospital of Hebei Medical University

    Shijiazhuang,
    China

    Site Not Available

  • The Second Affiliated Hospital of Xian Jiaotong University

    Xi'an,
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.